| MOPEE27 | Robot-based assessment: a novel tool to objectively quantify the impact of HIV on aging | Poster exhibition | Implementation science and scale up of treatment |
| MOPEE28 | Improving viral load suppression among children aged 0-14 years through community ART distribution in rural Uganda: lessons from Anyeke HCIV | Poster exhibition | Implementation science and scale up of treatment |
| OAA0102 | Resident microbiota enhance HIV acquisition, replication, and pathogenesis in vivo | Oral abstract session with live Q&A | HIV pathogenesis |
| OAA0103 | Gut dysfunction as an independent driver of neuroinflammation in ART-suppressed SIV | Oral abstract session with live Q&A | HIV pathogenesis |
| OAA0104 | Gut memory CD4+ T cells from people with HIV on suppressive ART express high levels of intracellular HIV sensors | Oral abstract session with live Q&A | HIV pathogenesis |
| OAA0105 | Are moto-neurons susceptible to SARS-CoV-2 infection? | Oral abstract session with live Q&A | SARS-CoV-2 virology, pathogenesis, and host immune responses, vaccines and immunotherapies |
| OAA0202 | Depletion of plasmacytoid dendritic cells in ART-suppressed SIV-infected rhesus macaques to reverse dysfunction and exhaustion of cytotoxic CD8+ T lymphocytes and perturb the SIV reservoir | Oral abstract session with live Q&A | Understanding and targeting persistent HIV reservoirs |
| OAA0203 | In vivo genome engineering of human T cells results in ART-free control of HIV-1 in humanized mice | Oral abstract session with live Q&A | Novel treatment and prevention strategies |
| OAA0204 | The EZH2 inhibitor Tazemetostat increases MHC-I antigen presentation in vitro and in vivo, enhancing antiviral activities of HIV-specific CTLs | Oral abstract session with live Q&A | Novel treatment and prevention strategies |
| OAA0205 | Anti-PD-1 chimeric antigen receptor T cells efficiently target SIV-infected CD4+ T cells in germinal centers of rhesus macaques | Oral abstract session with live Q&A | Novel treatment and prevention strategies |